对比增强CT的影像组学分析可预测肝细胞癌的微血管侵犯与结局
该研究回顾性纳入495例手术切除的肝细胞癌患者,整合6个靶体积的7260个影像组学特征构建R评分,并与15个临床因素和12个影像学评分一起建立影像学-影像组学(RR)模型。RR模型预测MVI的AUC在训练/验证集为0.909、测试集为0.889;RR预测MVI阳性与阴性组的中位PFS为12.9个月对49.5个月,中位OS为47.3个月对76.3个月。作者结论认为该计算方法的预测表现良好,但当前CT影像组学分析方案对影像学评分未提供统计学显著的附加价值。
要点
- 肿瘤大小与瘤内异质性相关影像组学特征是预测MVI排名靠前的特征。
- R评分预测MVI的OR为2.34,低于肿瘤包膜、肿瘤边缘和瘤周强化的OR。
- RR模型预测MVI的AUC在训练/验证集为0.909,在测试集为0.889。
核心结论
- 整合大规模临床-影像学与影像组学特征的计算方法在预测MVI和临床结局方面表现良好。
- 但当前CT影像组学分析方案对影像学评分未提供统计学显著的附加价值。
研究设计与样本
- 回顾性纳入495例手术切除的肝细胞癌患者。
- 从6个靶体积的7260个影像组学特征构建MVI相关影像组学评分(R评分)。
- 将6个R评分、15个临床因素和12个影像学评分通过多变量逻辑回归整合为影像学-影像组学(RR)模型。
主要发现
- 与肿瘤大小和瘤内异质性相关的影像组学特征是预测MVI排名靠前的特征,相关R评分按MVI状态差异显著(p<0.001)。
- 回归分析识别出8个MVI风险因素,包括5个影像学特征和1个R评分。
- R评分的OR为2.34,重要性低于肿瘤包膜(OR 5.12)、肿瘤边缘(OR 4.20)和瘤周强化(OR 3.03)。
- RR模型预测MVI的AUC在训练/验证集为0.909,在测试集为0.889。
- RR预测MVI阴性组与阳性组的中位PFS为49.5个月对12.9个月,中位OS为76.3个月对47.3个月,两组差异显著。
关键数值与推荐
- R评分预测MVI的OR为2.34。
- 肿瘤包膜预测MVI的OR为5.12,肿瘤边缘为OR 4.20,瘤周强化为OR 3.03。
- RR模型预测MVI的AUC在训练/验证集为0.909,在测试集为0.889。
- RR预测MVI阴性组与阳性组的中位PFS为49.5个月对12.9个月,中位OS为76.3个月对47.3个月。
临床怎么用
- 作者认为该计算方法可加强对患者治疗可能成功的沟通并指导临床管理。
- 作者提出其目标是寻找降低复发风险的药物。
- 作者结论指出当前CT影像组学分析方案对影像学评分未提供统计学显著的附加价值。
局限性
- 作者结论指出当前CT影像组学分析方案对影像学评分未提供统计学显著的附加价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Microvascular invasion (MVI) impairs surgical outcomes in patients with hepatocellular carcinoma (HCC). As there is no single highly reliable factor to preoperatively predict MVI, we developed a computational approach integrating large-scale clinical and imaging modalities, especially radiomic features from contrast-enhanced CT, to predict MVI and clinical outcomes in patients with HCC. METHODS: In total, 495 surgically resected patients were retrospectively included. MVI-related radiomic scores (R-scores) were built from 7,260 radiomic features in 6 target volumes. Six R-scores, 15 clinical factors, and 12 radiographic scores were integrated into a predictive model, the radiographic-radiomic (RR) model, with multivariate logistic regression. RESULTS: Radiomics related to tumor size and intratumoral heterogeneity were the top-ranked MVI predicting features. The related R-scores showed significant differences according to MVI status (p <0.001). Regression analysis identified 8 MVI risk factors, including 5 radiographic features and an R-score. The R-score (odds ratio [OR] 2.34) was less important than tumor capsule (OR 5.12), tumor margin (OR4.20), and peritumoral enhancement (OR 3.03). The RR model using these predictors achieved an area under the curve (AUC) of 0.909 in training/validation and 0.889 in the test set. Progression-free survival (PFS) and overall survival (OS) were significantly different between the RR-predicted MVI-absent and MVI-present groups (median PFS: 49.5 vs. 12.9 months; median OS: 76.3 vs. 47.3 months). RR-computed MVI probability, histologic MVI, tumor size, and Edmondson-Steiner grade were independently associated with disease-specific recurrence and mortality. CONCLUSIONS: The computational approach, integrating large-scale clinico-radiologic and radiomic features, demonstrates good performance for predicting MVI and clinical outcomes. However, radiomics with current CT imaging analysis protocols do not provide statistically significant added value to radiographic scores. LAY SUMMARY: The most effective treatment for hepatocellular carcinoma (HCC) is surgical removal of the tumor but often recurrence occurs, partly due to the presence of microvascular invasion (MVI). Lacking a single highly reliable factor able to preoperatively predict MVI, we developed a computational approach to predict MVI and the long-term clinical outcome of patients with HCC. In particular, the added value of radiomics, a newly emerging form of radiography, was comprehensively investigated. This computational method can enhance the communication with the patient about the likely success of the treatment and guide clinical management, with the aim of finding drugs that reduce the risk of recurrence.
引用
- Xu X, Zhang HL, Liu QP, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol. 2019. PMID: 30876945. doi:10.1016/j.jhep.2019.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。